A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study

Journal:

Blood

Published:

2026-04-09

DOI:

10.1182/blood.2025029971

Affiliations:

7

Authors:

16

Go to article

Institutions	Authors	Share
NIH National Heart, Lung, and Blood Institute (NHLBI), United States of America (USA)	12.000000 12.000000	0.75
NIH National Cancer Institute (NCI), United States of America (USA)	2.000000	0.13
NIH Clinical Center, United States of America (USA)	1.000000	0.06
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	0.500000	0.03
Hospital of the University of Pennsylvania, Penn, United States of America (USA)	0.500000	0.03

Interested in Cardiovascular Medicine and Haematology?